Abstract
The androgen receptor (AR) is a nuclear hormone receptor that plays a key role in the development of the prostate and progression of prostate cancer (PCa). AR is the initial target for treatment in hormone dependent PCa, where inhibition of AR activity results in a decrease in tumor volume and increased survival. However, PCa often returns as castration-resistant prostate cancer (CRPC) due to several factors including AR overexpression, reactivation of the full-length receptor (AR-FL), and expression of constitutively activate truncated AR-variants (AR-Vs) that lack the ligand binding domain. Upon reactivation of AR-FL and expression of AR-Vs, traditional methods of treatment targeting the ligand binding domain are ineffective. Targeting the evolutionarily conserved N-terminal domain, DNA binding domain (DBD) or using transcription factors that interact with AR will be key in developing new treatments for PCa.
This is a preview of subscription content, log in via an institution to check access.
References
Agoulnik IU, Weigel NL. Coregulators and the regulation of androgen receptor action in prostate cancer. In: Tindall D, Mohler J, editors. Androgen action in prostate cancer. New York: Springer; 2009. p. 315–40.
Azad AA, Zoubeidi A, Gleave ME, Chi KN. Targeting heat shock proteins in metastatic castration-resistant prostate cancer. Nat Rev Urol. 2015;12(1):26–36.
Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 2008;6:e001.
Bennett NC, Gardiner RA, Hopper JD, Johnson DW, Gobe GC. Molecular cell biology of androgen receptor signaling. Int J Biochem Cell Biol. 2010;42(6):813–27.
Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, et al. Selectively targeting DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem. 2014;289(38):26417–29.
Gupta A, Lilja H, Schroeder FH. Detection of prostate cancer: PSA. In: Tindall DJ, Scardino PT, editors. Recent advances in prostate cancer basic science discoveries and clinical advances. Singapore: World Scientific; 2011. p. 283–334.
Kokontis JM, Lin H, et al. Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of the cdk2, cyclin A, and Skp2. Plos One. 2014;9(10):e109170.
Lonergan PE, Tindall DJ. Truncated androgen receptor splice variants in prostate cancer. In: Tindall DJ, editor. Prostate cancer biochemistry, molecular biology and genetics. New York: Springer; 2013. p. 351–82.
Lu J, Van der Steen T, Tindall DJ. Are androgen receptor variants a substitute for the full-length receptor? Nat Rev Urol. 2015;12(3):137–44.
Mohler JL, Titus MA, Godoy AS, Oka D, Nelson PS. Intracrine synthesis of androgens by prostate cancer in response to androgen deprivation therapy. In: Tindall DJ, Scardino PT, editors. Recent advances in prostate cancer basic science discoveries and clinical advances. Singapore: World Scientific; 2011. p. 193–218.
Myung J, Banuelos CA, et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest. 2013;123(7):2948–60.
Nuclear Receptor Signaling Atlas. Baylor College of Medicine, Houston. 2014. http://www.nursa.org. Accessed 10 Mar 2015.
Ruscetti MA, Wu H. PTEN in prostate cancer. In: Tindall DJ, editor. Prostate cancer biochemistry, molecular biology and genetics. New York: Springer; 2013. p. 87–138.
Sahu B, Pihaljamaa P, Dubois V, Kerkhofs S, Claessen F, Janne OA. Androgen receptor uses relaxed response element stringency for selective chromatin binding and transcriptional regulation in vivo. Nucleic Acids Res. 2014;42(7):4230–40.
Stein MN, Patel N, Bershadskiy A, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl. 2014;16(3):387–400.
Suzman DL, Antonarakis ES. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol. 2014;6(4):167–79.
The Androgen Receptor Gene Mutations Database World Wide Web Server. McGill University, Montreal. 2014. http://www.androgenb.mcgil.ca. Accessed 24 Feb 2015.
Van der Steen T, Tindall DJ, Huang H. Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci. 2013;14(7):14833–59.
Vander Griend DJ, Isaacs JT. Androgen receptor as a licensing factor for DNA replication. In: Tindall D, Mohler J, editors. Androgen action in prostate cancer. New York: Springer; 2009. p. 619–30.
Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM. Biological and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer. 2014;21(4):T87–103.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this entry
Cite this entry
Van der Steen, T., Schmidt, L.J., Tindall, D.J. (2015). AR, Overview. In: Marshall, J. (eds) Cancer Therapeutic Targets. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6613-0_111-1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6613-0_111-1
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Online ISBN: 978-1-4614-6613-0
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences